Evidence map›Paper›PMID 30380806›Full record

ArticleCells2018

Pilot Production of Mesenchymal Stem/Stromal Freeze-Dried Secretome for Cell-Free Regenerative Nanomedicine: A Validated GMP-Compliant Process.

Elia Bari, Sara Perteghella, Dario Di Silvestre, Marzio Sorlini, Laura Catenacci, Milena Sorrenti, Giorgio Marrubini, Rossana Rossi, Giuseppe Tripodo, Pierluigi Mauri and 2 more

Abstract read
In one paragraph

Article in Cells, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Elia BariDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy. elia.bari@unipv.it.ORCID 0000-0003-0241-0620
Sara PerteghellaDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy. sara.perteghella@unipv.it.ORCID 0000-0003-1128-7636
Dario Di SilvestreInstitute for Biomedical Technologies, F.lli Cervi 93, 20090 Segrate, Milan, Italy. dario.disilvestre@itb.cnr.it.ORCID 0000-0002-7143-6229
Marzio SorliniPharmaExceed srl, 27100 Pavia, Italy. marzio.sorlini@supsi.ch.
Laura CatenacciDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy. laura.catenacci@unipv.it.
Milena SorrentiDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy. milena.sorrenti@unipv.it.ORCID 0000-0001-8249-5761
Giorgio MarrubiniDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy. giorgio.marrubini@unipv.it.ORCID 0000-0003-1399-5783
Rossana RossiInstitute for Biomedical Technologies, F.lli Cervi 93, 20090 Segrate, Milan, Italy. rossana.rossi@itb.cnr.it.
Giuseppe TripodoDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy. giuseppe.tripodo@unipv.it.ORCID 0000-0001-5462-5629
Pierluigi MauriInstitute for Biomedical Technologies, F.lli Cervi 93, 20090 Segrate, Milan, Italy. pierluigi.mauri@itb.cnr.it.ORCID 0000-0003-4364-0393
Mario MarazziTissue Therapy Unit, ASST Niguarda Hospital, Piazza Ospedale Maggiore 3, 20162 Milan, Italy. mario.marazzi@ospedaleniguarda.it.
Maria Luisa TorreDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy. marina.torre@unipv.it.ORCID 0000-0001-8062-6836

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this paper, a pilot production process for mesenchymal stem/stromal freeze-dried secretome was performed in a validated good manufacturing practice (GMP)-compliant cell factory. Secretome was purified from culture supernatants by ultrafiltration, added to cryoprotectant, lyophilized and characterized. We obtained a freeze-dried, "ready-off-the-shelf" and free soluble powder containing extracellular vesicles and proteins. In the freeze-dried product, a not-aggregated population of extracellular vesicles was detected by nanoparticle tracking analysis; Fourier transform infrared spectra showed the simultaneous presence of protein and lipids, while differential scanning calorimetry demonstrated that lyophilization process successfully occurred. A proteomic characterization allowed the identification of proteins involved in immune response, response to stress, cytoskeleton and metabolism. Moreover, the product was not cytotoxic up to concentrations of 25 mg/mL (on human fibroblasts, chondrocytes and nucleus pulposus cells by MTT assay) and was blood compatible up to 150 mg/mL. Finally, at concentrations between 5 and 50 mg/mL, freeze-dried secretome showed to in vitro counteract the oxidative stress damage induced by H₂O₂ on nucleus pulposus cells by MTT assay.

Indexed as

exosomefreeze-dryingmesenchymal stem cellsmicrovesiclessecretomeultrafiltration

Identifiers

PMID30380806
PMCPMC6262564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.